Conference Details - Overview

Back to Conferences

Continuing Education Information

Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit™

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Sixth Annual Symposium on the Future of Lung Cancer

Washington Marriott Hotel
Washington, DC
December 5, 2009

Conference Overview

Summary and Purpose

CME-Certified Symposium

This activity is presented by Physicians’ Education Resource in conjunction with National Comprehensive Cancer Network

The Sixth Annual Symposium on the Future of Lung Cancer is an educational and scientific meeting designed to provide state-of-the-art information on the management of patients with non–small-cell lung cancer (NSCLC). In partnership with the National Comprehensive Cancer Network (NCCN), this program will outline the state-of-the-art approaches to locally advanced and metastatic NSCLC. In addition, expert faculty will describe the impact of tumor histology on choice of therapy, explore controversies such as the timing of maintenance therapy, and discuss the optimal application of inhibitors of angiogenesis and the EGFR pathway. The next generation of targeted agents, including inhibitors of EML4-ALK, IGF-1R, HDACs, HSP90, and mTOR will be introduced. As targeted agents become established in the metastatic setting, much effort will be made to use these agents to benefit patients with earlier stages of disease, including locally advanced NSCLC. Finally, surgical approaches to resectable stage III NSCLC will be explored. This program will include didactic lectures, debates, expert discussion panels, and ample time to interact with the faculty. Attendees will receive the benefit of learning about NCCN state-of-the-art approaches as well as emerging strategies for lung cancer treatment.

Target Audience

This educational program is directed toward medical oncologists, radiation oncologists, basic scientists, translational researchers, and other health care professionals with an interest in new developments in the treatment of lung cancer. Fellows, nurses, physician assistants, and pharmacists with an interest in lung cancer are also invited to attend.

Learning Objectives

At the conclusion of this symposium you should be able to:

  • Analyze the relationship between tumor histology and response to and toxicity with therapy in lung cancer
  • Summarize criteria for the selection and use of maintenance therapy in metastatic disease
  • Evaluate the efficacy and safety of EGFR inhibitors in lung cancer therapy
  • Assess the efficacy and adverse event profile of antiangiogenic agents in NSCLC
  • Outline the multidisciplinary interaction necessary to optimize local control of locoregional disease
  • Summarize the safety and efficacy of novel targeted and cytotoxic agents in stage III NSCLC
  • Discuss emerging targeted agents in development for NSCLC

Educational Grants

An educational grant for this activity was provided by:


  1. Boehringer Ingelheim Pharmaceuticals, Inc.
  2. Eli Lilly and Company
  3. Genentech BioOncology/
    OSI Oncology
  4. Merck Oncology
  6. Agennix, Inc.
  7. Novartis Oncology